Catalyst Dossier · compiled by Celia 🧫

Novo Nordisk A/S (NVO)

Pharmaceutical Preparations · market cap $203.2B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Novo Nordisk A/S (NVO) is a Danish pharmaceutical giant with ~68,800 employees and a $203B market cap, anchored in diabetes and obesity franchises (semaglutide, insulin portfolio) with a broad late-stage pipeline spanning cardiometabolic, rare bleeding, and cardiovascular inflammation. The most important near-term catalysts are three readouts for Ziltivekimab in cardiovascular risk (October–December 2026) and an NDA filing for Etavopivat in Sickle Cell Disease (December 2026), alongside continued Phase 3 execution across obesity (cagrilintide) and ATTR-CM (NNC6019-0001).

The catalyst path

2026-08-05Earningsimp 5/10
2026-09-01 (est.)Phase 2 · NNC0519-0130imp 7/10
2026-10-01 (est.)Phase 3 · Ziltivekimabimp 9/10
2026-10-05 (est.)Phase 3 · Ziltivekimabimp 9/10
2026-11-23 (est.)Phase 3 · insulin glargineimp 9/10
2026-12-14 (est.)Phase 3 · Ziltivekimabimp 9/10
2026-12-14 (est.)Phase 2 · NNC0662-0419imp 7/10
2026-12-31 (est.)NDA Filing · Etavopivatimp 8/10

Pipeline

Asset	Phase	Indication
NNC6019-0001	Phase 3	Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Semaglutide 1.0 mg	Phase 3	Obesity
CDR132L	Phase 2	Heart Failure
biphasic insulin aspart	Phase 3	Diabetes
NNC109-0012	Phase 2	Inflammation
Cagrilintide	Phase 3	Obesity or Overweight
Concizumab	Phase 3	Congenital Bleeding Disorder
sitagliptin	Phase 3	Diabetes
biphasic human insulin	Phase 3	Diabetes
Insulin Icodec	Phase 3	Diabetes Mellitus, Type 2
Semaglutide (administered by PDS290 pen)	Phase 2	Healthy Volunteers Diabetes Mellitus, Type 2
human insulin	Phase 3	Diabetes
insulin 338 (GIPET I)	Phase 2	Diabetes
insulin NPH	Phase 3	Diabetes
metformin	Phase 3	Diabetes
NNC0662-0419	Phase 2	Overweight
turoctocog alfa pegol	Phase 3	Congenital Bleeding Disorder
rosiglitazone	Phase 3	Diabetes
biphasic insulin aspart 50	Phase 3	Diabetes
DPP-4 inhibitor	Phase 3	Diabetes

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.